Starting this autumn, adults aged 50 and older across the European Union may be able to roll up their sleeve just once and walk away protected against both COVID-19 and influenza. The European Commission in April 2026 granted marketing authorization for Moderna’s mCombriax, a single mRNA injection targeting both viruses. According to available regulatory records, the EU is the first jurisdiction to have approved a combined respiratory vaccine of its kind, though independent confirmation that no other regulator acted earlier has not been fully established.
For the millions of older Europeans who routinely skip one or both annual shots because of the hassle of booking two appointments or simple reluctance to endure multiple injections, the approval addresses a stubborn public health problem. Seasonal influenza alone kills an estimated 20,000 to 40,000 people across the EU in a typical year, according to the European Centre for Disease Prevention and Control, and COVID-19 continues to cause thousands of additional deaths annually among older adults.
What the authorization covers
The European Commission’s decision applies to all 27 EU member states and is limited to adults 50 and older. It followed a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific body of the European Medicines Agency, which adopted its recommendation ahead of the Commission’s April 2026 decision. The authorization has been formally entered into the EU Union Register of medicinal products, giving it legal force across the bloc.
The vaccine contains mRNA sequences encoding three influenza strains (A/H1N1, A/H3N2, and B/Victoria) alongside a SARS-CoV-2 component, according to the EMA’s product record. That four-target design mirrors the composition of standard quadrivalent flu vaccines but adds coronavirus protection in the same syringe.
The clinical evidence behind the decision
The EMA’s assessment rested on a trial of approximately 8,000 participants aged 50 and older. Researchers compared immune responses from the single combination shot against responses from two separate injections: Moderna’s existing COVID vaccine Spikevax paired with either Fluzone HD or Fluarix, both established flu vaccines.
The EMA concluded that mCombriax demonstrated non-inferior immune responses compared to those two-shot regimens. In practical terms, the combination vaccine triggered antibody levels at least as strong as the individual shots given together. The agency also reviewed safety data and found the side-effect profile to be consistent with what is already known about mRNA vaccines: injection-site pain, fatigue, headache, and muscle aches were among the most commonly reported reactions.
One important caveat: the trial’s primary endpoint measured immune response, not real-world disease prevention. Strong antibody levels are a well-established predictor of protection, but they are not the same as proving the shot prevents hospitalizations and deaths at the same rate as separate vaccines over a full flu season. That kind of effectiveness data has not yet been publicly released.
What is still unresolved
EU-level marketing authorization does not mean the vaccine will appear in pharmacies next week. Each member state negotiates its own pricing, reimbursement, and procurement terms. Some countries may fold mCombriax into their autumn 2026 vaccination campaigns quickly; others may wait for additional post-authorization safety monitoring before committing public funds. The rollout timeline will vary significantly from one country to the next.
Moderna has not publicly detailed its manufacturing capacity for mCombriax or confirmed whether the SARS-CoV-2 component will be updated seasonally to match circulating variants, a process already standard for flu strains. The company’s broader pipeline includes potential combination vaccines targeting respiratory syncytial virus (RSV) as well, but those remain in development rather than under active regulatory review.
No EU-level analysis has yet quantified how much a single-shot regimen could improve vaccination uptake among older adults. Public health officials have long argued that simplifying the process would help, but the actual impact on coverage rates remains theoretical until the vaccine is widely available and tracked through a full season.
The full clinical study report, including raw efficacy and safety data broken down by age subgroup and prior vaccination history, has not been made public. The EMA’s European Public Assessment Report provides a structured summary, but independent scientists cannot fully verify the non-inferiority finding or assess whether certain populations responded differently until peer-reviewed publications of the pivotal trial appear in medical journals.
Where the rest of the world stands
Based on publicly available regulatory announcements as of May 2026, no other major regulator has authorized a combined flu-COVID vaccine. The U.S. Food and Drug Administration has been reviewing Moderna’s combination vaccine data but has not yet issued a decision. The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has also not announced an authorization. By acting when it did, the European Commission set a reference point that other agencies will likely weigh as they evaluate similar applications.
Independent health policy outlets, including CIDRAP at the University of Minnesota, have confirmed the authorization and noted its significance within Moderna’s broader strategy to build a portfolio of combination respiratory vaccines.
What this means for patients planning ahead
For adults 50 and older in the EU, the practical takeaway is straightforward but time-dependent. The legal authorization is in place, yet the earliest realistic window for widespread availability is autumn 2026, when seasonal vaccination campaigns typically begin. Those interested should check with their national health service or physician as that window approaches.
In the meantime, existing separate COVID and flu vaccines remain available and effective. Skipping vaccination entirely while waiting for the combination option would be the worst outcome, particularly for older adults at highest risk from both infections.
Whether Europe’s early move on a combined mRNA respiratory vaccine translates into a global shift toward single-shot seasonal protection will depend on factors no single authorization can settle: real-world effectiveness data collected over full respiratory seasons, manufacturing scale, national willingness to pay, and whether public confidence in mRNA technology remains durable enough to sustain demand year after year.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
